Home / Weight & Metabolism / Retatrutide
Research reference · Weight & Metabolism
Retatrutide Retatrutide is an investigational peptide studied at the GLP-1, GIP and glucagon receptors. Phase 3 trials have been reporting since May 2026, and the sponsor plans to file for FDA approval in early 2027.
Published by Elevated Pharma · Updated November 7, 2026
Weight & Metabolism Phase 3 clinical research
Overview What’s new Key studies Identity data Sources
Identity
What is Retatrutide? An investigational triple-receptor agonist (development code LY3437943) that activates GIP, GLP-1 and glucagon receptors.
Research context
What has Retatrutide been studied for? Published phase 3 trials now include TRIUMPH-1 (NEJM, 2026), TRIUMPH-2 and TRANSCEND-T2D-1 (Lancet, 2026), alongside the 2023 phase 2 trial. Sponsor-reported results add TRIUMPH-3, TRIUMPH-4 and a head-to-head comparison with semaglutide.
Evidence boundary
What does the research not show? Trial results describe the sponsor’s investigational drug in the studied populations. They do not establish the identity, quality or safety of any independently sourced material.
U.S. status · November 7, 2026
Is Retatrutide FDA-approved? Investigational. Lilly states retatrutide is legally available only to participants in its clinical trials and plans to submit it for FDA review in the first quarter of 2027.
Upcoming November 8, 2026TRIUMPH-4 at ACR Convergence Lilly presents the 68-week phase 3 TRIUMPH-4 trial in knee osteoarthritis pain as a plenary; knee data from TRIUMPH-1 follow on November 10.
Read the source October 28, 2026 First head-to-head phase 3 Sponsor-reported TRANSCEND-T2D-2 results compare retatrutide with semaglutide 2 mg in type 2 diabetes over 80 weeks. Full results are not yet published.
Read the source September 29, 2026 TRIUMPH-1 and TRIUMPH-2 published TRIUMPH-1 appeared in NEJM and TRIUMPH-2 in The Lancet.
Read the source July 23, 2026 TRIUMPH-2 and TRIUMPH-3 topline Lilly reported topline results and said it plans to submit to FDA in Q1 2027.
Read the source
Key studies
The main Retatrutide research Selected from PubMed: human trials first, then reviews, then foundational laboratory work. Each finding applies to the material and setting studied.
Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity.
Study type Human RCT · phase 3
Journal · year · PMID N Engl J Med · 2026 · 42814954
What it covers TRIUMPH-1: 80-week trial in 2,339 adults with obesity or overweight without diabetes. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.
Study type Human RCT · phase 3
Journal · year · PMID Lancet · 2026 · 42810372
What it covers TRIUMPH-2: adults with obesity and type 2 diabetes. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1).
Study type Human RCT · phase 3
Journal · year · PMID Lancet · 2026 · 42250575
What it covers First phase 3 diabetes trial in the program. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
Study type Human RCT · phase 2
Journal · year · PMID N Engl J Med · 2023 · 37366315
What it covers The 48-week phase 2 obesity trial that led to the phase 3 program. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.
Study type Human RCT · phase 2
Journal · year · PMID Nat Med · 2024 · 38858523
What it covers Liver-fat substudy in people with fatty liver disease. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.
Study type Human RCT · phase 2
Journal · year · PMID Lancet Diabetes Endocrinol · 2025 · 40609566
What it covers Measures lean and fat mass changes. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials.
Study type Trial design
Journal · year · PMID Diabetes Obes Metab · 2026 · 41090431
What it covers How the TRIUMPH program was designed. Retatrutide in adults with obesity and type 2 diabetes: what have we learned from TRIUMPH-2?
Study type Commentary
Journal · year · PMID Lancet · 2026 · 42849462
What it covers Independent commentary on TRIUMPH-2. Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA.
Study type Network meta-analysis
Journal · year · PMID Obesity (Silver Spring) · 2025 · 40685589
What it covers Indirect comparison across incretin drugs; not a head-to-head trial. Detection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC-HRMS: Implications for Antidoping Analysis.
Study type Analytical method
Journal · year · PMID Rapid Commun Mass Spectrom · 2026 · 42745421
What it covers Mass-spectrometry method for identifying retatrutide. Search all 216 PubMed records for Retatrutide · Counts and selections checked November 7, 2026.
Reference identifiers
Retatrutide identity data Database identity describes the reference substance, not any specific material or lot.
Primary name Retatrutide
Also indexed as LY3437943
Official & primary sources
Regulatory and database records Citation does not imply an Elevated Pharma partnership or endorsement.